Dépistage des cancers de l'ovaire : chez qui, comment et pour quelle efficacité ?

Considering the prognostic difference between stage I, II and stage III, IV of ovarian carcinoma, it was licit to assess the opportunity to perform systematic screening. The available tools are Ca125 and transvaginal ultrasound, which have together a positive predictive value superior to 10% and are thus adapted to such a screening. The recent, randomized studies do not conclude on the efficacy and the cost-effectiveness of ovarian cancer screening for women with standard risk, but also for women presenting an increased risk.